title: Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
abstract: OBJECTIVE
  The adjuvant effects of probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori (H. pylori) infection have not been evaluated.
  
  
  METHODS
  A total of 337 patients with persistent H. pylori infection, after first-line triple therapy, were randomly assigned to receive either triple therapy with (yogurt group, n=151) or without (control group, n=186) Will yogurt. Triple therapy consisted of 400 mg moxifloxacin q.d., 1000 mg amoxicillin b.i.d., and 20 mg esomeprazole b.i.d. for 14 days. Will yogurt contains Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, and Streptococcus thermophilus. H. pylori eradication was evaluated by the (13)C-urea breath test, histology, or the rapid urease test.
  
  
  RESULTS
  The eradication rates by intention-to-treat analysis were 66.7% and 68.9% in the control and yogurt groups, respectively (P=0.667). The eradication rates by per-protocol analysis were 78.5% and 86% in the control and the yogurt groups, respectively (P=0.110). The adverse event rates were 25.3% and 28.5% in the control group and yogurt group, respectively (P=0.508).
  
  
  CONCLUSIONS
  The addition of yogurt containing probiotics to moxifloxacin-containing second-line treatment neither improved H. pylori eradication rates nor reduced the adverse events of treatment.
authors.affiliation: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Hyuk
authors.initials: H
authors.lastname: Yoon
authors.forename: Nayoung
authors.initials: N
authors.lastname: Kim
authors.forename: Ji Yeon
authors.initials: JY
authors.lastname: Kim
authors.forename: So Youn
authors.initials: SY
authors.lastname: Park
authors.forename: Ju Hee
authors.initials: JH
authors.lastname: Park
authors.forename: Hyun Chae
authors.initials: HC
authors.lastname: Jung
authors.forename: In Sung
authors.initials: IS
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use; D001644:Bifidobacterium / Q000254:growth & development; D001944:Breath Tests; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D064098:Esomeprazole / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D007779:Lactobacillus acidophilus / Q000254:growth & development; D007780:Lacticaseibacillus casei / Q000254:growth & development; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D019936:Probiotics / Q000009:adverse effects; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use; D056910:Republic of Korea; D048249:Streptococcus thermophilus / Q000254:growth & development; D013997:Time Factors; D016896:Treatment Outcome; D014510:Urease / Q000378:metabolism; D015014:Yogurt / Q000009:adverse effects / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D054328:Proton Pump Inhibitors; D011804:Quinolines; D000658:Amoxicillin; D014510:Urease; D064098:Esomeprazole; D000077266:Moxifloxacin